Natural CD4 CD25 FOXP3 regulatory T cells in graftversus-host disease - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 267

[169] Fohse L, Suffner J, Suhre K, Wahl B, Lindner C, Lee CW, et al. High TCR diversity en-
sures optimal function and homeostasis of Foxp3+ regulatory T cells. Eur J Immunol
2011;41:3101-13.
[170] Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al.
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med 2006;355:1018-28.
[171] Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell
subsets with antibody-cytokine immune complexes. Science 2006;311:1924-7.
[172] Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, et al. In vivo ex-
pansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and
long-term acceptance of islet allografts without immunosuppression. J Exp Med
2009;206:751-60.
[173] Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3
expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mecha-
nism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
[174] Beyer M, Schumak B, Weihrauch MR, Andres B, Giese T, Endl E, et al. In vivo expansion
of naive CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carci-
noma after IL-2 administration. PLoS One 2012;7:e30422.
[175] Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleu-
kin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-
66.
[176] Schmidl C, Hansmann L, Andreesen R, Edinger M, Hoffmann P, Rehli M. Epigenetic
reprogramming of the RORC locus during in vitro expansion is a distinctive feature of
human memory but not naive Treg. Eur J Immunol 2011;41:1491-8.
[177] Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibi-
tion promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299-
307.
[178] Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, et al. In vivo administration
of hypomethylating agents mitigates graft-versus-host disease without sacrificing graft-
versus-leukemia. Blood 2010;116:129-39.
[179] Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, et al. Azacitidine aug-
ments expansion of regulatory T cells after allogeneic stem cell transplantation in
patients with acute myeloid leukemia (AML). Blood 2012;119:3361-9.
[180] Becker C, Taube C, Bopp T, Michel K, Kubach J, Reuter S, et al. Protection from graft-
versus-host disease by HIV-1 envelope protein gp120-mediated activation of human
CD4+CD25+ regulatory T cells. Blood 2009;114:1263-9.
[181] Regateiro FS, Howie D, Cobbold SP, Waldmann H. TGF-beta in transplantation toler-
ance. Curr Opin Immunol 2011;23:660-9.
[182] Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A. Expansion of peripheral naturally
occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood
2009;113:6277-87.
[183] Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and
immunity. Immunity 2011;35:13-22.
[184] Chambers ES, Hawrylowicz CM. The impact of vitamin D on regulatory T cells. Curr
Allergy Asthma Rep 2011;11:29-36.

270